Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00852644 · ClinicalTrials.gov registry record · NA

Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

A NA study, sponsored by Boston Medical Center.

Terminated
Registry status
NA
Development phase
9
Enrollment target

NCT00852644 is a NA study that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 9 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00852644, a NA study, was terminated before completion, sponsored by Boston Medical Center.

TERMINATED
Registry status
NA
Development phase
9 participants
Enrollment target

Study Summary

RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiosurgery in treating patients with stage I or stage II non-small cell lung cancer.

Interventions

  • RADIATION fludeoxyglucose F 18
  • PROCEDURE computed tomography
  • RADIATION hypofractionated radiation therapy
  • RADIATION stereotactic radiosurgery

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2009-01
Est. Completion 2016-08
Phase NA

Sponsor

Boston Medical Center

253 total trials

What the Registry Record Tells You About NCT00852644

The ClinicalTrials.gov registry entry for NCT00852644 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which fludeoxyglucose F 18 is the first listed.

NCT00852644 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00852644 about?

NCT00852644 is a clinical study titled "Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer". RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiosurgery in treating patients with stage I or stage II non-small cell lung cancer.

What is the current status of trial NCT00852644?

This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2009-01. Estimated completion is 2016-08.

What interventions are being tested in trial NCT00852644?

The interventions under investigation include: fludeoxyglucose F 18 (RADIATION), computed tomography (PROCEDURE), hypofractionated radiation therapy (RADIATION), stereotactic radiosurgery (RADIATION).

Who is sponsoring clinical trial NCT00852644?

This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.